ALEC
USDAlector Inc. Common Stock
Preço em tempo real
Gráfico de preços
Métricas-chave
Métricas de mercado
Abertura
$1.400
Máximo
$1.435
Mínimo
$1.290
Volume
1.77M
Fundamentos da empresa
Capitalização de mercado
133.6M
Setor
Biotecnologia
País
United States
Estatísticas de negociação
Volume médio
2.62M
Bolsa de valores
NMS
Moeda
USD
Faixa de 52 semanas
Notícias relacionadas
Clinical Failure Halts Alector's Dementia Program, Company Reduces Workforce
Alector's Phase 3 trial for FTD-GRN drug, latozinemab, failed the clinical co-primary endpoint. The program is discontinued; Alector cuts 49% of staff.
TD Cowen Downgrades Alector to Hold
TD Cowen analyst Yaron Werber downgrades Alector from Buy to Hold.
Cantor Fitzgerald Downgrades Alector to Neutral
Cantor Fitzgerald analyst Pete Stavropoulos downgrades Alector from Overweight to Neutral.
HC Wainwright & Co. Maintains Buy on Alector, Lowers Price Target to $5
HC Wainwright & Co. analyst Andrew Fein maintains Alector with a Buy and lowers the price target from $10 to $5.
William Blair Downgrades Alector to Market Perform
William Blair analyst Myles Minter downgrades Alector from Outperform to Market Perform.
BTIG Downgrades Alector to Neutral
BTIG analyst Thomas Shrader downgrades Alector from Buy to Neutral.
Alector Announces Topline Results from Latozinemab Phase 3 Trial in Individuals with Frontotemporal Dementia Due to a GRN Mutation and Provides Business Update
SOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progression of
Ações relacionadas
Mantenha-se atualizado
Defina um alerta de preço, obtenha atualizações de análise de IA e notícias de mercado em tempo real.